A randomized phase 3 study comparing once-daily elvitegravir with twice-daily raltegravir in treatment-experienced subjects with HIV-1 infection: 96-week results (Q42287613)

From Wikidata
Jump to navigation Jump to search
scientific article published on August 2013
edit
Language Label Description Also known as
English
A randomized phase 3 study comparing once-daily elvitegravir with twice-daily raltegravir in treatment-experienced subjects with HIV-1 infection: 96-week results
scientific article published on August 2013

    Statements

    A randomized phase 3 study comparing once-daily elvitegravir with twice-daily raltegravir in treatment-experienced subjects with HIV-1 infection: 96-week results (English)
    Richard Elion
    José Ramón Arribas López
    Franco Maggiolo
    Edmund Wilkins
    Brian Conway
    Ya-Pei Liu
    Nicolas Margot
    Martin Rhee
    Steven L Chuck
    Javier Szwarcberg
    Study 145 Team
    1 August 2013
    494-497

    Identifiers

     
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    edit